
RealRate

PHARMACEUTICAL 2019

Savara Inc Rank 172 of 371





RealRate

PHARMACEUTICAL 2019

Savara Inc Rank 172 of 371



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Savara Inc is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 197% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	113,344
Cost of Goods Sold	0
Intangible Assets	26,918
Liabilities, Current	7,254
Liabilities, Non-Current	0
Other Assets	11,503
Other Compr. Net Income	-758
Other Expenses	13,707
Other Liabilities	36,814
Other Net Income	18
Property and Equipment	522
Research and Development	37,173
Revenues	0
Selling, General and Administrative Expense	10,654

Output Variable	Value in 1000 USD
Assets	152,287
Liabilities	44,068
Expenses	61,534
Stockholders Equity	108,219
Net Income	-61,516
Comprehensive Net Income	-61,895
Economic Capital Ratio	-135%

